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Sodium pump
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Receptor-operated channelSalt retention as a result of chronic, excessive dietary salt intake, is widely accepted as one of the most
common causes of hypertension. In a small minority of cases, enhanced Na+ reabsorption by the kidney can
be traced to speciﬁc genetic defects of salt transport, or pathological conditions of the kidney, adrenal cortex,
or pituitary. Far more frequently, however, salt retention may be the result of minor renal injury or small
genetic variation in renal salt transport mechanisms. How salt retention actually leads to the increase in
peripheral vascular resistance (the hallmark of hypertension) and the elevation of blood pressure remains an
enigma. Here we review the evidence that endogenous ouabain (an adrenocortical hormone), arterial
smooth muscle α2 Na+ pumps, type-1 Na/Ca exchangers, and receptor- and store-operated Ca2+ channels
play key roles in the pathway that links salt to hypertension. We discuss cardenolide structure–function
relationships in an effort to understand why prolonged administration of ouabain, but not digoxin, induces
hypertension, and why digoxin is actually anti-hypertensive. Finally, we summarize recent observations
which indicate that ouabain upregulates arterial myocyte Ca2+ signaling mechanisms that promote
vasoconstriction, while simultaneously downregulating endothelial vasodilator mechanisms. In sum, the
reports reviewed here provide novel insight into the molecular mechanisms by which salt retention leads to
hypertension.iversity of Maryland School of
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Hypertension, or chronic high blood pressure (BP) is a major
contributor to ischemic heart disease, cerebrovascular disease, heart
failure and renal failure, and is estimated to cause more than 7 million
premature deaths per year worldwide [1]. Appropriate treatment, and
even prevention, of hypertension depends upon better understanding
of the underlying causes and mechanisms of the elevated BP. Despite
extensive research during the past few decades, some critical
questions about the pathogenesis of elevated BP remain unanswered.
Here, we focus on recent ﬁndings that provide novel insight into the
linkage between salt retention and hypertension.
2. Kidneys, salt retention and hypertension
The kidneys, which play the primary role in salt and water balance,
have long been at the center of hypertension research. The kidneyglomeruli of a 70 kgman ﬁlter ∼25,000 mEq of Na+ and 180 l of water
per day, and then reabsorb nearly 99.5% of this ﬁltered load by a
variety of Na+ transport mechanisms [2]. It is not surprising,
therefore, that defects in any mechanisms that alter renal Na+
transport may contribute to the net gain or loss of salt (and water).
The association of hypertension with renal parenchymal diseases
[3,4], monogenic diseases of renal salt transport [5–7] and renal
transplant studies [8–10], as well as Guyton's seminal work on the
“over-riding dominance of the kidneys” in controlling BP [11–13], all
point to the critical role of the kidneys in hypertension. Likewise,
epidemiological studies as well as acute and chronic dietary studies
[14,15], volume expansion studies [13,16–18], the efﬁcacy of diuretic
therapy [19], and monogenic diseases of renal salt transport [5,6,20],
all indicate that NaCl retention and a tendency toward plasma volume
expansion [21] play a fundamental role in the chronic elevation of BP.
Conversely, genetic defects that reduce salt retention, such as those
associated with Bartter's and Gittelman's syndromes, tend to lower
BP and protect against the development of hypertension [22]. Never-
theless, the speciﬁc mechanism(s) responsible for salt retention in
most forms of human essential hypertension (EH) is(are) unresolved.
Perhaps subtle renal damage [23], which increases with age, including
that which may result from obesity [24,25], causes salt retention.
Importantly, any of several genetic variants (single nucleotide
1 This long-term, or day-to-day, whole body autoregulation, can be distinguished
temporally and, therefore, almost certainly mechanistically, from the minute-to-
minute autoregulation that maintains constant blood ﬂow in, for example, the brain or
kidney vasculature.
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kinase type 4 [26–28], alpha-adducin [29,30], or serine/threonine
kinase (STK39) [31] genesmay favor salt retention by the kidneys and,
therefore, predispose the bearers of these genes to salt-dependent
hypertension. It is apparent, however, that in virtually all of these
situations, extracellular ﬂuid (ECF) neither progressively increases
nor decreases. Instead, homeostatic physiological (feedback) mecha-
nisms come into play to protect against ECF volume changes [21]. As
we shall see, some of these mechanisms may alter BP to defend
against changes in plasma (and ECF) volume.
3. Vascular tone
A related, unresolved issue in hypertension, and our main focus, is
the speciﬁc mechanism(s) or “signaling pathway” by which salt
retention actually elevates BP [32]. To explore this pathway, we begin
with some basic hemodynamic principles: Mean arterial BP is a
function of cardiac output (CO), heart rate (HR), stroke volume (SV)
and total peripheral vascular resistance (TPR) [33]. At constant CO,
mean BP≈CO×TPR. CO, which is equal to HR×SV, is, in turn, directly
related to the ECF volume and the volume of venous return to the
heart. TPR is regulated dynamically by vasoconstriction/dilation in
small “resistance” arteries by three groups of mechanisms: barore-
ﬂexes and other neuro-humoral mechanisms, endothelial mecha-
nisms, and myogenic mechanisms [33]. The local (myocyte and
endothelial) factors that maintain tonic arterial constriction, or ‘tone’,
can be studied in isolated, cannulated small arteries. These arteries
develop spontaneous ‘myogenic’ tone (MT) when the lumen is
pressurized [34,35]. Indeed, the level of tone in isolated arteries “is
often comparable to that observed in the same vessels in vivo” [34,35],
and may even be used to predict BP changes [36].
Hypertension has often been associated with structural changes
that decrease the lumen-to-wall thickness ratio and increase wall
stiffness [37–39] due to vascular remodeling [40,41]. It is not clear,
however, whether this vascular remodeling is usually the cause or the
effect of the hypertension. Recently, we reported that, in some
hypertension models, most of the increase in TPR can be attributed to
functional, and not structural, alterations in small resistance arteries
[42]. Here, we will explore the basis of the dynamic, reversible arterial
functional changes, the augmented tone and contractile responses
that are observed in hypertension [43,44]. To understand the
generation of vascular tone, it is prudent to examine the fundamental
mechanisms that inﬂuence arterial myocyte contraction. Wewill start
with themechanisms that regulatemyocyte Ca2+ because contraction
is activated by a rise in the cytosolic Ca2+ concentration, [Ca2+]CYT
[45].
4. Ca2+ homeostasis and arterial constriction
Arterial constriction/dilation and, thus, BP are under neural
control, and are also regulated by various endocrine and paracrine
substances. Especially noteworthy is the role of the endothelium,
which normally tends to restrict excessive vasoconstriction by
secretion of nitric oxide (NO) and other vasodilatory factors [46]. In
small “resistance arteries”, MT induced by intra-vascular pressure
[34,35], plays a key role in controlling BP.
At the cellular level, contraction depends directly on [Ca2+]CYT and
the activation of myosin light chain kinase by Ca2+-calmodulin, as
well as on modulation of the contractile apparatus' sensitivity to Ca2+
(e.g., by Rho/Rho kinase) [47,48]. Myocyte [Ca2+]CYT is regulated by
various Ca2+ entry, exit and storage systems [45]. Ca2+ enters
myocytes from the ECF through voltage-gated, receptor-operated,
store-operated and stretch-activated channels (VGCs, ROCs, SOCs and
SACs, respectively; see Fig. 1). Most of the myocyte Ca2+ is seques-
tered in the sarcoplasmic reticulum (SR) by the sarco-/endoplasmic
reticulum Ca2+ pump (SERCA). Myocytes can be activated by varioushormones and neurotransmitters. For example, stimulation of the
sympathetic nerves that innervate the arteries releases norepineph-
rine (NE), ATP and neuropeptide Y, all of which contribute to acti-
vation of the myocytes [49]. Myocytes can also be activated by
increased intra-lumenal pressure and wall tension; this opens cation-
selective SACs, which depolarize themyocytes, thereby opening Ca2+-
selective VGCs. Neurotransmitter release, as well as NO release by the
endothelium, are also activated by a rise in [Ca2+]CYT in the respective
cell types, but the neurotransmitters promote myocyte contraction,
while NO antagonizes contraction. Nevertheless, Ca2+ homeostasis in
neurons and endothelial cells utilizes many of the same mechanisms
that operate in arterial myocytes.
Vasoconstrictors such as NE bind to agonist receptors (ARs), which
are G-protein coupled receptors (GPCRs) located in the myocyte
PM (Fig. 1). This induces the phospholipase C-mediated synthesis
of inositol trisphosphate (IP3) and diacylglycerol (DAG). The IP3
interacts with its receptors/channels (IP3Rs) on the SR membrane,
thereby releasing Ca2+ into the cytosol to activate contraction. Ca2+
(and Na+) [50,51] can also enter the cytosol from the ECF through
cation-selective ROCs (opened by DAG) and SOCs (opened by SR Ca2+
depletion). The Ca2+ can be re-sequestered in the SR by SERCA,
or it can be extruded from the myocytes by ATP-driven PM Ca2+
pumps (PMCA). Importantly, Ca2+ can also either exit or enter the
cells via the Na+/Ca2+ exchanger (NCX) which is driven by the Na+
electrochemical gradient across the PM under the control of the Na+
pumps [52]. NCX uniquely links Na+ metabolism to Ca2+ regulation
and, thus, to arterial myocyte constriction. These mechanisms provide
critical insight into the question of how salt retention elevates BP.5. Whole body autoregulation
A seminal advance in elucidating the pathophysiology of hyper-
tension was the introduction of the concept of long-term1 “whole
body autoregulation” of blood ﬂow [53] and its experimental
veriﬁcation [16,18,54,55]. These studies showed that salt retention
and consequent plasma volume expansion initially elevates BP
because of an increase in CO. With sustained volume expansion,
even for just a few days, however, the CO declines and TPR increases
to maintain the elevated BP [54]. Thus, relatively normal CO and
elevated TPR are routinely observed in established hypertension [11].
Nevertheless, in experimentally-induced hypertension, for example
with mineralocorticoids [55] or renal artery clipping [56], a transient
initial state of increased CO can often be detected. Failure to observe
this high CO stage could be the result of compensatory mechanisms
(“autoregulation”) that turn on very shortly after the volume starts to
expand. In most humans with (essential) hypertension, salt retention
and (tendency toward) volume expansion likely occur gradually, over
days to years. In that case, the mechanisms that tend to lower plasma
volume and CO, including the rise in TPR and pressure natriuresis
[12,54,57], likely operate simultaneously to prevent an overt increase
in CO. This corresponds to a condition of “virtual hypervolemia,”
however, because blood volume is still inappropriately high relative to
the BP [21]. Importantly, the effects of volume expansion on TPR and
BP are rapidly reversed if the stimulus (e.g., the volume load or the
mineralocorticoid and salt) is withdrawn [54,55,57,58]. This implies
that the (initial) rise in TPR must be functional and not structural, and
it must almost certainly be hormonal because this “autoregulation”
involves all of the vasculature, veins as well as arteries, and pul-
monary as well as systemic vessels [59].
Fig. 1.Model of the plasma membrane-junctional sarco-/endoplasmic reticulum (PM-jS/ER) region, the PLasmERosome, showing the location of key transport proteins involved in
local control of jS/ER Ca2+ stores and Ca2+ signaling. The PLasmERosome consists of a PMmicrodomain, the adjacent jS/ER (with SERCA, IP3R and ryanodine receptors, RYR), and the
intervening ‘diffusion-restricted’ junctional space (J). The PM microdomain contains agonist receptors, ARs (GPCRs), ROCs and SOCs (composed of various transient receptor
potential channel proteins or TRPCs), α2 (in smooth muscle) or α3 Na+ pumps, and NCX. Activation of GPCRs and release of G-proteins (GPs) stimulates phospholipase C (PLC) to
produce IP3 and diacylglycerol (DAG). DAG may activate ROCs directly. Na+ may enter locally, through ROCs, SOCs or, perhaps, SACs (not shown) to promote Ca2+ entry via NCX.
Shading indicates relative Na+ and/or Ca2+ concentrations. Other regions of the PM contain α1 Na+ pumps and PMCA. Other abbreviations are deﬁned in the text.
Reprinted with permission from [184].
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term autoregulation, efforts to elucidate the speciﬁc underlying
mechanisms have been surprisingly scant. In the mid-1970s, we
[60] and others [61] raised the possibility that an endogenous Na+
pump inhibitor, i.e., a ouabain-like compound with vasotonic action,
might be secreted in response to salt retention and plasma volume
expansion. In other words, this substance might be a missing
hormonal link between salt retention, and the increased TPR and
hypertension. Strict conservation of the high afﬁnity ouabain-binding
site amino acid sequence throughout mammalian evolution implies
that there must be an endogenous ligand that interacts with this site.
We suggested that partial Na+ pump inhibition by the endogenous
inhibitor should promote the net gain of Ca2+ via the myocyte NCX,
and thereby augment Ca2+ signaling and vasoconstriction [59,60]. The
central roles of these three molecular entities, the endogenous Na+
pump inhibitor, Na+ pumps and NCX, is described below. New
evidence that certain TRPC proteins, components of Ca2+- and Na+-
permeable ROCs and SOCs [50,51], also make key contributions to the
altered Ca2+ signaling [62], is discussed as well.6. Endogenous ouabain and its receptor
The aforementioned ideas fueled the search for the postulated
endogenous Na+ pump inhibitor, a ligand for the pump's cardiotonic
steroid (CTS) binding site, that might mediate the vascular response.
In 1991, we puriﬁed endogenous ouabain (EO) from human plasma;
the endogenous substance was identiﬁed as ouabain by mass
spectroscopy [63]. It is now possible to quantitate EO by liquid
chromatography–tandem mass spectroscopy (LC–MS–MS) methods
[64] starting from small (1 ml) samples of human or animal plasma
[65,66]. The idea that EO might be the 11β isomer of ouabain [67,68]
has been excluded because the 11-epimers of ouabain are chromatog-
raphically different [69].Rat adrenal cortex is highly enriched with EO, and human and cow
adrenals also contain very high levels [63]. Bilateral adrenalectomy
greatly reduces EO in rat plasma; conversely, treatment of uni-
nephrectomized rats with DOCA (deoxycorticosterone acetate)+salt
greatly increases plasma EO and elevates BP [63]. These ﬁndings
indicate that EO is an adrenocortical hormone. Other reports, how-
ever, suggest that EO may also be synthesized in, and secreted by,
the hypothalamus [70,71].
Numerous human and intact animal studies, as well as adreno-
cortical cell culture studies, indicate that EO is synthesized in the
adrenal cortex, and that its synthesis and secretion is stimulated by
adrenocorticotropic hormone (ACTH) [63,72–83]. In humans [79] and
animals [72,75], ACTH-induced hypertension is associated with
elevation of EO. Indeed, preliminary reports indicate that certain
rare adrenocortical tumors, which are associated with severe hyper-
tension, may produce prodigious amounts of EO [84,85]. In ACTH-
induced hypertension [75,86], as well as in DOCA-salt hypertension
[87] and reduced renal mass hypertension [88], BP is lowered by
Digibind (digoxin-selective Fab fragments), which also binds ouabain
with high afﬁnity [89].
About 50% of humans with untreated essential hypertension and a
majority of patients with adrenocortical adenomas and hyperten-
sion have signiﬁcantly elevated plasma EO; moreover, BP correlates
directlywith plasma EO [90–93]. Even in normal human subjects, a high
salt diet raises plasmaEO [66], anda10 min infusionof lowdoseouabain
increases vascular resistance and elevates BP for N60 min [94–96].
Critical support for the idea that EO might play a key role in the
pathogenesis of hypertension was the demonstration that pro-
longed administration of ouabain to normal rats induces hyperten-
sion [97] (Fig. 2). This observation has been replicated in many
laboratories [98–100].
Plasma EO levels are elevated in several rodent salt-sensitive
hypertension models [63,88,101–103], and chronic administration of
low dose ouabain to normal rodents usually induces hypertension in
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DOCA act synergistically to induce hypertension [104]. Ouabain-
induced BP elevation in rodents is counteracted by the ouabain
antagonist, Rostafuroxin (PST-2238) [105,106], and hypertension
induced by ACTH or DOCA+salt is antagonized by Digibind
[75,86,87].
The aforementioned ﬁndings are strong evidence that circulating
EO has a key role in the pathogenesis of salt-sensitive hypertension.
Other studies suggest, however, that brain, not plasma, EO [70], or
even marinobufagenin [70,107], may be important.
Interestingly, low dose ouabain increases TPR in dogs, but doesn't
raise BP, presumably because heart rate and CO are markedly reduced
[108]. Ouabain also doesn't induce hypertension in sheep [109] or in
mineralocorticoid-resistant [110] Long–Evans rats [111]. Such excep-
tions not only show that the genetic background is important, butmay
provide novel information to help clarify the relationship between EO
and hypertension.
Na+ pumps are widely accepted as the CTS receptor, but this
greatly oversimpliﬁes the situation. Na+ pumps are αβ heterodimers.
The catalytic subunit, α, contains the Na+, K+, ATP and ouabain-
binding sites, and is phosphorylated during each pump cycle. β is
essential for pump function; it stabilizes the α subunit conformation
and chaperones the αβ complex to the PM [112–114]. The 4
mammalian α subunit isoforms (α1–α4) are products of different
genes, but have nearly 90% sequence identity; they have different
expression patterns and different kinetics, and are differently
regulated [112,115–121]. Many (most) cell types express Na+
pumps with an α1 subunit and Na+ pumps with a second α isoform
[112,119,122]. Astroglia [123–125], endothelial cells [126], and all
types of muscles [42,112,127–129] express Na+ pumps with an α2
subunit as well as pumps with an α1; most neurons express α1 and
α3 [112,123,125,129]. Renal epithelia express predominantly (N90–
95%) Na+ pumps with α1, which mediate the ﬁnal step in net
transepithelial Na+ reabsorption [120,130].
The Na+ pump α subunit CTS binding site has been highly
conserved during the evolution of higher animals. Nevertheless, not
all α subunit isoforms, nor the isoforms in all species, have the same
high afﬁnity for CTS. For example, rodent α1 Na+ pumps have
unusually low afﬁnity for CTS [112,131]. Thus, it is important to
understand better both the CTS and their interactions with their Na+
pump α2 subunit binding sites.Fig. 2. Ouabain, but not digoxin, induces hypertension; digoxin and digitoxin reverse
ouabain-induced hypertension. Rats were infused with vehicle (■), ouabain, 15 μg/kg/
day (▼), or digoxin, 30 μg/kg/day (▲), for 42 days. From days 35 to 42, three groups of
8 ouabain-infused rats received a secondary infusion of digoxin, 30 μg/kg/day (●),
digitoxin, 30 μg/kg/day (○), or vehicle (▼). Mean blood pressures (MBP) were
obtained by tail cuff at weekly intervals or as indicated. *Pb0.05 vs ouabain; ***Pb0.001
vs ouabain; #Pb0.005 vs vehicle; **Pb0.001 vs digoxin.
Reprinted with permission from [99].7. The myriad uses and roles of cardiotonic steroids
Recorded use of CTS dates back more than 1500 years. CTS have
been employed not only as diuretics and cardiotonics, but as emetics,
as abortion agents, and as poisons. For more than two centuries
following William Withering's classic clinical study [132], Digitalis
glycosides were the drugs of choice for the treatment of congestive
heart failure and certain cardiac arrhythmias.
Recently, the novel roles of CTS and the Na+ pump in cancer
therapeutics, and mood/behavioral [133] and neurological disorders
[134] have been discussed. For example, one striking observation is
that mortality from breast cancer was markedly reduced in patients
on digitalis therapy [135]; this has prompted greatly renewed interest
in CTS and their possible role in cancer therapy [136–140]. In addition,
ideas about the action of EO as a natriuretic agent [60] have been
revived [141,142]. Furthermore, many observations now indicate that
EO also is a growth hormone: EO may participate in a variety of
kinase-mediated and other signaling pathways, independent of its
effects on Na+ pump-mediated Na+ transport [143–150]. This might
contribute, for example, to the target organ damage that often occurs
in hypertension.
8. Cardiotonic steroid structure–activity relationships:
hypertensinogenic and anti-hypertensinogenic cardenolides
Cardiotonic steroids have been widely used clinically to treat heart
failure and cardiac arrhythmias. It has long been accepted that the
cardiotonic effect of CTS results from their ability to inhibit Na pumps
(Na,K-ATPase) [151] and thereby promote Ca2+ entry via NCX
[152,153]. The CTS include two structurally distinct groups — the
cardenolides, in which the steroid is attached to a ﬁve member singly
unsaturated lactone ring (Fig. 3, Table 1), and the bufadienolides, in
which the lactone has six members and is doubly unsaturated. When
one or more sugars are attached to the CTS at carbon 3, they are
termed ‘cardiac glycosides’; common examples include ouabain and
digoxin. With the exception of the bufanolide, proscillaridin, the
steroid nucleus (aglycone) in the common bufadienolides is usually
not glycosylated, but it may be conjugated with suberyl arginine or
various other congeners.
Cardenolides and bufadienolides are synthesized in certain plants,
some amphibians and insects, and possibly all higher animals. Crude
as well as highly enriched extracts from plants and the parotid
secretions of the toad have been used in homeopathic remedies to
treat heart failure and some cancers, and as general tonics for
metabolism and immune function, especially in China (e.g., Chan Su)
and Japan (Senso). The advent of modern pharmacology, coupled with
the desire to use purer preparations in therapy, led to extensive
studies on the Digitalis and Strophanthus glycosides and their
aglycones, and the more prominent entities in toad secretions,
including bufalin and resibufagenin.
Most research on CTS, and on various natural and synthetic
analogs, has focused on the positive inotropic response (enhanced
contraction) of heart preparations, and on the inhibition of isolated
kidney enzyme (Na,K-ATPase). Thus, the bulk of knowledge about the
structure–activity relationships is relevant to the heart, or to (renal)
Na+ pumps with an α1 catalytic subunit. Overall, the inotropic
response appears to be correlated with the ability to bind and inhibit
the Na+ pump. Introduction of various substitutions in the steroid
nucleus and lactone ring indicates that the conﬁguration of the steroid
is crucial for these effects.
The classic adrenocortical, ovarian and testicular steroids lack the
cis–trans–cis fusion of the AB, BC, and CD rings found in the CTS
(Fig. 3, Table 1), and do not bind to, or inhibit, the Na+ pump. Certain
steroids with trans–trans–cis ring fusions are cardiotonic [154,155],
while those with cis–trans–trans ring fusions (e.g., common bile salts,
14α-digitoxigenin and 14α-artebufogenin) are either inactive or very
Fig. 3. Prototypical cardenolide steroid skeleton. The primary feature is a steroid
skeleton with the rings fused in a cis–trans–cis arrangement. The cardenolides dis-
cussed here have a 14βOH, an unsaturated lactone ring attached via C17 in the β
conﬁguration, and a methyl group at C18. When present, sugars are attached via the
steroid 3βOH group. See Table 1 for the list of substituents in ouabain, ouabagenin,
digoxin, digitoxin and Rostafuroxin.
Reprinted with permission from [99].
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steroid nucleus increases the potency, while inversion of the lactone
conﬁguration at C17 from β to α [158], or saturation (e.g., dihydrooua-
bain and dihydrodigoxin) of the lactone ring, reduces the cardiotonic
activity 10–30 fold. These fundamental relationships, obtained with
cardiac preparations, have been widely assumed to be valid in other
physiological systems.
Both ouabain and digoxin, when administered acutely in vivo, and
often in high doses, induce vasoconstriction [95,159–164]. Nanomolar
ouabain, however, augments myogenic constriction in rodent isolated
arteries [36,42,65,165,166]. The ﬁrst experimental evidence of a
previously-unrecognized cardenolide structure–activity relationship
was the observation that the prolonged administration of digoxin, also
an Na,K-ATPase inhibitor [167], does not raise BP in normal rats,
whereas ouabain does (Fig. 2) [168]. This result has been conﬁrmed by
several investigators [99,100,169,170]. Moreover, while digoxin itself
does not raise BP [171], digoxin and a related CTS, digitoxin, are very
effective in lowering the elevated BP in rats with ouabain-induced
hypertension (Fig. 2) [99,100]. Importantly, digoxin also is known to
lower BP in hypertensive humans [172]. These remarkable observa-
tions can only be explained by structural differences between the
Strophanthus (e.g., ouabain) and Digitalis steroids, even though they
are ostensibly similar Na+ pump inhibitors. The sugar(s) is(are) not
crucial for these effects: the aglycone of ouabain, ouabagenin
(Table 1), is also pro-hypertensive [173], while Rostafuroxin, a
derivative of digitoxigen [174], is anti-hypertensive in humans and
rats [105,106]. Thus, differences in the steroid moieties of digoxin/
digitoxin and ouabain account for their disparate effects on long-term
BP. Excluding the common oxygen at C3, ouabain is hydroxylated in
positions 1,5,11,14 and 19, while digoxin is hydroxylated in positions
12 and 14 (Table 1). The major structural difference between the twoTable 1
Some relevant cardenolides and their substituents.
Compound Steroid substituenta Sugar at C3
1β 5β 11α 12β 17α 19
Ouabain OH OH OH H H CH2OH Rhamnose
Ouabagenin OH OH OH H H CH2OH None
Digoxin H H H OH H CH3 Digitoxose (3)
Digitoxin H H H H H CH3 Digitoxose (3)
Digitoxigenin H H H H H CH3 None
Rostafuroxin H H H H OH CH3 None
a The common cardenolides have a 5-member singly unsaturated lactone ring in the
17β position, but Rostafuroxin has a doubly unsaturated furane substituent at this
position.steroids therefore lies in the extensive hydroxylation of ouabain in the
A and B rings (and well away from the lactone ring) and the 12
hydroxyl group in digoxin. Like digoxin and ouabain, Rostafuroxin has
a steroid nucleus that is cis–trans–cis fused and has a 14β hydroxyl
group. However, it lacks the ouabain hydroxyls at positions 1,5,11 and
19 and the lactone has been replaced with a doubly unsaturated
furane [174].
In sum, the key structural components that underlie the long-term
pressor activity of the cardenolides appear to include a steroid nucleus
whose rings are fused in a cis–trans–cis conﬁguration with oxygen-
ation of the AB ring at C5. The depressor activity of the cardenolides
appears to be linked with the cis–trans–cis steroid conﬁguration,
deoxygenation of the AB ring at C5 and substituents at C17 that
augment potency as Na+ pump inhibitors including unsaturated 5-
and 6-member lactone rings. Many of the naturally occurring
cardenolides are mixtures of structural features at opposite ends of
the steroid nucleus that confer prolonged pressor and depressor
activity in vivo. Synthetic analogs with either improved pressor or
depressor activity, the latter exempliﬁed by Rostafuroxin, may be of
clinical relevance. Clearly, the physiology and pharmacology of these
agents is still full of surprises.
9. The “PLasmERosome”: a structural basis for ouabain's action
The roles of the different α subunit isoforms were clariﬁed by the
discovery that, in arterial smooth muscle (ASM) and other cell types,
Na+ pumps with the α2 or α3 subunit were conﬁned to PM
microdomains situated adjacent to “junctional” sarco-/endoplasmic
reticulum (jS/ER) (Fig. 1) [117,118]. Na/Ca exchangers are conﬁned to
the same PM microdomains (Fig. 1) [118], as are various TRPC proteins
[175] that are components of ROCs and SOCs [176–178]. In contrast, Na+
pumps with an α1 subunit are more ubiquitously distributed in the PM,
but are apparently excluded from these PMmicrodomains [122,179,180].
The functional as well as structural interrelationship of these transport
proteins is supported by the remarkable observation that ASM α2 (but
not α1) Na+ pumps, NCX1, and TRPC6 and -1, are all upregulated by
prolonged ouabain administration, both in vivo and in vitro [176].
The PM microdomains are separated by only 12–20 nm from the
jS/ER [181], and these structures form a functional unit, the
“PLasmERosome” [182,183]. The volume of cytosol in the junctional
space (J) between the PM and jS/ER of a single PLasmERosome (Fig. 1)
is on the order of only 10−19 to 10−18 l, and diffusion of Na+ and Ca2+
between this space and bulk cytosol is restricted. Thus, standing Na+
and Ca2+ concentration gradients between these compartments and
bulk cytosol can be maintained [51,127,131,179,184,185].
Differences in Na+ pump α subunit isoform kinetics are the key to
PLasmERosome function. Rodent α1 has an unusually low afﬁnity for
ouabain (KOuabainN100 µM, vs b0.05 µM in humans) [112,131]; thus,
nanomolar ouabain inhibits only the α2 Na+ pumps in rodent arterial
myocytes. Even in humans, however, whereα1 Na+ pumps have high
afﬁnity for ouabain, partial inhibition of Na+ pumps by nanomolar
ouabain will elevate [Na+] in the junctional space much more than in
bulk cytosol. The reason is that the afﬁnity of α2 Na+ pumps for Na+
is much lower (KNa≈22 mM) than is the afﬁnity of α1 Na+ pumps
(KNa≈12 mM) [121].
The broad distribution of α1 Na+ pumps implies that they control,
primarily, [Na+] in bulk cytosol. In contrast, pumps with an α2
(in smoothmuscle, for example) or α3 catalytic subunit regulate local
[Na+] in the junctional space. Thus, these α2/α3 Na+ pumps control
the local Na+ electrochemical gradient that inﬂuences Ca2+ transport
by the adjacent NCX. The ROCs and SOCs located here (Fig. 1) are
cation-selective channels that admit Na+ as well as Ca2+ [50].
This organizational arrangement (Fig. 1) links Na+ metabolism to cell
Ca2+. Thus, the transporters in the PLasmERosome regulate not only
[Ca2+] in the junctional space, but S/ER Ca2+ stores and global Ca2+
signaling in the cells as well [182,183]. Therefore, modulation of α2
Fig. 4. Relative blood pressures of mice with genetically engineered α2 Na+ pumps and
NCX1. The data from several sources, are normalized to the BPs of the respective control
wild type (WT) mice. Mice with a null mutation in one α2 Na+ pump allele (α2+/−)
[36] or smooth muscle-speciﬁc α2 knockdown (α2SM/DN) (Song, Chen, Zhang, Lee,
Kotlikoff and Blaustein, unpublished), or increased smooth muscle-speciﬁc NCX1
overexpression (NCX1SM/Tg) [166], had signiﬁcantly elevated BP. A high salt diet
augmented the elevated BP in α2+/− mice (4% NaCl×2 weeks) and NCX1SM/Tg mice
(8% NaCl+1% NaCl in tap water×4 weeks). Smooth muscle-speciﬁc overexpression of
α2 Na+ pumps (α2SM/Tg) [187] or knockdown of NCX1 (NCX1SM−/−) [198] sig-
niﬁcantly reduced BP. *=Pb0.05, **=Pb0.01 vs WT or the respective genotypes on a
normal (0.5%) salt diet.
Reprinted with permission from [65].
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arterial tone and BP. In the ensuing discussion we summarize data
from recent experiments in which genetic engineering and pharma-
cological manipulation of mouse Na+ pumps and NCX have been used
to examine the roles of these transporters in the long-term control of
BP.
10. How does ouabain (EO) elevate blood pressure? The
downstream effector mechanisms
10.1. α2 Na+ pumps
The fact that chronic administration of exogenous ouabain induces
hypertension in rodents has already been mentioned. The questions
we now address are: How does ouabain (or EO) elevate BP? Is it due
to inhibition of smooth muscle α2 Na+ pumps, as implied by the
preceding discussion?
We have reported that acute application of nanomolar ouabain to
isolated, pressurized rodent arteries with myogenic tone augments
the tone. The EC50 is on the order of 1 nM ouabain in intact arteries,
and even lower in arteries without endothelium [36,42].
If circulating ouabain (or EO) elevates BP by inhibiting ASM α2
Na+ pumps, reduced expression of α2 Na+ pumps should have a
similar effect. Indeed, mice with a null mutation in one α2 Na+
pump allele (α2+/−) [128] express ∼50% of the normal complement
of α2 in arteries [36,127] and have elevated BP (Fig. 3) [36,165].
Mice with a null mutant α1 allele (α +/−) express half the normal
complement of α1 Na+ pumps, but have normal BP (Fig. 4) [36,165].
Moreover, mesenteric small arteries from the α2+/−, but not α1+/−
mice, exhibit augmented myogenic reactivity and myogenic tone
(MT).[36] The α2+/− mice are also “salt-sensitive”: a high salt diet
increases BP much more in these mice than in their wild type
littermates (Fig. 4).
The α2+/− mice are “global” single allele null mutants, but it is
important to determine if the effects are the result of reduced α2 Na+
pump activity/expression in ASM. Recently, we found that expression
of a short N-terminal segment of the α2 Na+ pump was dominant
negative (DN) for expression of full-length α2 pumps [180].
Therefore, we generated mice (α2SM/DN) that expressed the N-
terminal segment with a smooth muscle (SM)-speciﬁc myosin heavy
chain promoter [186]. Thesemice, with greatly reducedα2 Na+ pump
expression in artery smooth muscle, have elevated BP (Fig. 4).
Conversely, mice that overexpress α2, but not those that overexpress
α1, Na+ pumps in smooth muscle, have, on average, signiﬁcantly
reduced BP compared to wild type (WT) mice (Fig. 4) [187].
The roles of ouabain/EO and α2 Na+ pumps in elevating BP was
also examined in two other ways. We tested Rostafuroxin, which
antagonizes the inhibitory action of ouabain on Na,K-ATPase [188]. In
isolated arteries, Rostafuroxin counteracts the augmentation of MT by
nanomolar ouabain, but not the (ouabain-independent) augmenting
effect of reduced α2 expression on MT [36]. Rostafuroxin also lowers
BP in ouabain-induced hypertension [105,106] and in nearly 50% of
humans with essential hypertension [105].
Alternatively, mice that expressed mutant, ouabain-resistant α2
pumps (α2R/R) [75,115,189] are resistant to ACTH-induced hyper-
tension [75,115] as well as to ouabain-induced hypertension [189].
These results demonstrate that ACTH-induced and ouabain-induced
hypertension depend a high afﬁnity cardiotonic steroid binding site
on the α2 Na+ pump. The hypertension also depends upon a water-
soluble ligand that binds to this site because the plasma level of this
ligand (presumably EO) is increased by ACTH and, like ouabain [89],
binds to Digibind with high afﬁnity [189].
The studies on mice with genetically altered α2 Na+ pumps reveal
that arterial myocyte α2 Na+ pumps mediate the effects of EO
and play a role in the long-term regulation of BP. Genetically or
pharmacologically reducedα2 activity elevates BP, whereas increasedα2 activity lowers BP. It is not yet clear, however, how to reconcile
these results with the evidence that isoouabain, with a saturated
lactone ring tethered to C14 of steroid ring D, is hypertensinogenic,
but a poor inhibitor ofα1 Na+ pumps [173]. One possibility is that CTS
structure–function relations may be different for α1 and α2 Na+
pumps.10.2. NCX type-1
The next question is: By what speciﬁc mechanism does the altered
α2 Na+ pump activity inﬂuence BP? The answer appears to lie in Na/
Ca exchange, which directly links Na+ to Ca2+ metabolism and is a
distal regulator of cytosolic Ca2+. There are two classes of Na/Ca
exchangers, those that co-transport K+ with Ca2+ (NCKX), and those
that do not (NCX) [190]. Although NCKX has been found in ASM [191],
the dominant exchanger in arterial myocytes is NCX. There are three
mammalian NCX isoforms (NCX1–NCX3), each the product of a
different gene [192]. NCX1, which is expressed in ASM, has multiple
splice variants; NCX1.3 is the dominant variant in ASM [193].
Studies on primary cultured rat arterial myocytes indicated that
inhibition of Na+ pumps by nanomolar ouabain augments Ca2+
signaling without elevating bulk cytosolic Na+ [182]. Even knockout
of α2 Na+ pumps in cultured cells (astrocytes) had only minimal
effect on bulk cytosolic Na+, but a large effect on Ca2+ signaling [194].
These results are consistent with a functional linkage between α2
(but not α1) Na+ pumps and NCX1, and local reduction of the trans-
PM Na+ gradient when α2 activity is reduced, as implied by the
PLasmERosome model (Fig. 1). Also, recent pharmacological and
genetic engineering studies reveal that NCX1 inﬂuences not only
arterial myocyte Ca2+ metabolism, but long-term vascular tone and
BP as well.
Mice inwhichNCX1 is overexpressed in smoothmuscle (NCX1SM/Tg)
have elevated BP that is markedly increased by a high salt diet (i.e., the
mice are “salt-sensitive”) (Fig. 4) [166]. The elevated BP in the NCX1
overexpressors on high dietary salt is abolished by SEA0400, a selective
NCX1 inhibitor [195], but not if the overexpressed NCX1 contains a
G833C mutation [166], which speciﬁcally antagonizes the action of
SEA0400 [196].
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(NCX1ﬂx/ﬂx) [197] were crossed with mice containing a Cre
recombinase gene under the control of the smooth muscle myosin
heavy chain promoter [186] to generate smoothmuscle-speciﬁc NCX1
knockout (NCX1SM−/−) mice. These NCX1SM−/− mice have abnor-
mally low blood pressure (Fig. 4), and isolated, pressurized small
arteries from these mice have abnormally low MT [198]. Indeed,
SEA0400 also lowers BP by about 5–10 mm Hg in WT mice [166] and
reducesMT by about 10% in isolated arteries from thesemice [36,166].
Thus, NCX1 activity apparently makes a small, but direct, contribution
to normal MT and BP. SEA0400 also attenuated the increased MT in
arteries from α2+/−mice [36], indicating that NCX1 mediates effects
that are distal to those of theα2 Na+ pumps. The BP andMT data from
α2+/− and NCX1SM−/− mice support the view that MT in isolated
arteries is an in vitro reﬂection of BP [34] and, most likely, TPR.
The mice with genetically engineered NCX1 demonstrate that
this exchanger contributes to long-term BP regulation: increased
NCX1 expression increases BP, while knockout of NCX1 reduces BP.
This view is also supported by the effects of NCX blockers in several
rodent models of salt-dependent or ACTH-induced hypertension. In
DOCA+salt hypertensive rats, spontaneously hypertensive rats
(SHR) on a high salt diet, and Dahl salt-sensitive rats on high salt,
SEA0400 markedly reduced BP [166]. Also, KB-R7943, a less potent
blocker, prevents ACTH from elevating BP in mice.[75] Moreover,
although a null mutation in one NCX1 allele has negligible effect on
BP (NCX+/− in Fig. 4) or MT [198], it does prevent the induction of
hypertension by DOCA+salt [166]. Importantly, SEA0400 does
not lower BP in several salt-independent rat hypertension models:
SHR on a normal salt diet, stroke prone-SHR, and the renin-
dependent two-kidney/one-clip rat [166]. The implication is that
NCX1 contributes to the pathogenesis of salt-dependent hyperten-
sion, but not to salt-independent hypertension. As detailed else-
where [65], these ﬁndings reveal that NCX1, along with SACs, ROCs
and L-type VGCs, contribute to the elevated [Ca2+]CYT that generates
and maintains MT and, thus, inﬂuences TPR and BP.11. The central role of Ca2+ signaling
At the outset, we noted that arterial myocyte contraction depends,
ultimately, upon the availability of cytosolic Ca2+, and the sensitivity
of the contractile apparatus to that Ca2+. NCX1, under the control of
the Na+ gradient generated by the adjacent α2 Na+ pumps, helps
regulate myocyte Ca2+ homeostasis (Fig. 1). For example, nanomolar
ouabain-induced increases in MT are associated with increases in
myocyte [Ca2+] [36]; conversely, reduction of MT by SEA0400 is
associated with reduced myocyte [Ca2+] [166]. Thus, α2 Na+ pumps
and NCX1 are relatively distal mechanisms in the ﬁnal common path
that links salt to vasoconstriction and hypertension. Indeed, all
upstream vasoconstrictor and vasodilator mechanisms (neural and
humoral) must, inevitably, be inﬂuenced by the activity of these two
transporters [165].
As an alternative, it was recently suggested that activation of Rho/
Rho kinase via the G12–G13-mediated G-protein coupled receptor
pathway, which modulates the Ca2+ sensitivity of the contractile
apparatus in ASM, is selective for salt-dependent hypertension [199].
Interference with the G12–G13 pathway, however, whether at the
agonist receptor level [200], or at the level of Rho kinase [201], also
lowers BP in salt-independent models such as the stroke-prone
spontaneously hypertensive rat (SPSHR) [200] and the NO synthase-
inhibited rat [201]. In our view, the ﬁndings ofWirth et al. [199] better
ﬁt the view that, once salt-sensitive NCX1-mediated Ca2+ entry has
occurred [65], the G12–G13 pathway becomes a critical determinant of
the increases in vascular tone and BP. The G12–G13 pathway is,
therefore, downstream, and distinct from the key salt-sensitive steps
in Na+-dependent hypertension.12. Acute vs chronic effects of ouabain on the vasculature and
blood pressure
Much of the preceding discussion concerns, primarily, the acute
actions of ouabain on the vasculature. Nanomolar ouabain increases
the myogenic reactivity of normal rodent arteries with a time course
of seconds to minutes, and with an apparent EC50 (concentration
for half-maximal effect) of 0.6–1.3 nM [36,42]. A comparable effect
is observed in arteries isolated from rats with ouabain-induced
hypertension [42]. Nevertheless, in vivo ouabain administration
(∼15–30 μg/kg/day), whether by injection, subcutaneous pellet, or
osmotic minipump, elevates BP very slowly. BP usually rises with a
delay, and takes about 14–21 days to plateau (Fig. 2) [97,99]. A likely
explanation for this slow rise, despite the increased myogenic
reactivity, is that normal feedback mechanisms defend the BP and
counteract the elevation. Important examples include the barorecep-
tor reﬂex and local endothelium-initiated vasodilator mechanisms
[33]. With maintained administration, however, the BP slowly begins
to rise (Fig. 2) [97,99] as the chronic effects of ouabain become
manifest and feedback controls are downregulated or reset.
Ca2+ signaling is altered by prolonged ouabain treatment in both
arterial smooth muscle and endothelium, but in different directions.
Arterial smooth muscle from rats with ouabain-induced hypertension
exhibits upregulation of the protein components of the “Ca2+
signaling pathway” that includes the α2 Na+ pumps, NCX1, and
TRPC6 and TRPC1 (the latter two are components of ROCs and SOCs,
respectively; see Fig. 2) [176]. The consequently enhanced Ca2+
signaling further augments myogenic reactivity and vasoconstrictor-
evoked responses [42].
Acute administration of low dose ouabain also promotes Ca2+
signaling in the endothelium, and thereby augments vasodilator
mechanisms such as the response to acetylcholine [126]. Importantly,
however, these endothelial mechanisms are impaired in arteries from
rats with ouabain-induced hypertension [126]. In other words, at the
local (vascular) level, prolonged exposure to ouabain enhances the
vasoconstrictor mechanisms in the arterial smooth muscle while,
simultaneously, downregulating the endothelial feedback mecha-
nisms that normally help prevent the BP from rising. The net effect, of
course, is the development of hypertension.
These ﬁndings may have much broader relevance to the
pathogenesis of hypertension. In many forms of human and animal
hypertension, including the DOCA-salt model and the Dahl salt-
sensitive model (both of which are associated with high EO levels),
endothelial vasodilator mechanisms [202–205] and baroreﬂexes
[206–208] are impaired, while vasoconstrictor responses are aug-
mented [44,203,205].
13. Coda
In this review, we have explored some of the critical steps that link
salt retention to the elevation of BP. Recent results, especially those
from chemical analyses of human and rodent plasma samples, and
from genetic engineering and pharmacological studies in rodents and
rodent arteries, are summarized above. These studies give new insight
into some of the molecular events that help regulate cytosolic Ca2+
and vascular tone. The data provide compelling evidence that EO,
smooth muscle α2 Na+ pumps, NCX1, and TRPC channel proteins, are
key molecular links in the pathway that leads from salt retention to
hypertension.
These ﬁndings provide a framework, but the story is far from
complete. A key area where knowledge is lacking is at the early steps
between plasma volume expansion and the release of EO. The
astonishing difference between the actions of ouabain and digoxin
on BP demonstrate that cardenolide structure–activity relationships
need to be better understood. Even the central role of the kidneys is
still not completely resolved: For example, the renal and extra-renal
1226 M.P. Blaustein, J.M. Hamlyn / Biochimica et Biophysica Acta 1802 (2010) 1219–1229arteries make apparently independent (and equal) contributions
to the long-term regulation of BP [34,209], but how the distal
mechanisms, discussed above, affect the renal and extra-renal
vasculature and renal function, and thereby contribute to BP control,
is still unexplored. The progress outlined here should help identify
new directions for hypertension research to resolve these issues.
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